Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 7.0% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. (TNDM) specializes in diabetes management products, such as insulin pumps.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 7.0% on Feb 3, 2026 17:27

• TNDM faced a downward trend following the announcement of a voluntary medical device correction for its t:slim X2 insulin pumps.
• The correction addressed a possible speaker-related issue that could disrupt insulin delivery, sparking concerns about the product's reliability.
• A probe by the Rosen Law Firm into potential securities claims exacerbated the negative sentiment surrounding TNDM and led to a significant drop in the stock price.
• Investors reacted strongly to these developments, reflecting apprehensions about the potential impact on Tandem Diabetes Care's financial performance and reputation.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following a significant stock drop. This investigation comes after the company issued a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could stop insulin delivery. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm regarding a potential class action lawsuit to recover losses.

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302675392.html

TNDM Investor News: If You Have Suffered Losses in Tandem

The Rosen Law Firm is investigating potential securities claims on behalf of investors in Tandem Diabetes Care, Inc. (NASDAQ: TNDM). This follows a significant stock drop after the company announced a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm to join a prospective class action lawsuit.

https://www.globenewswire.com/fr/news-release/2026/01/27/3227129/0/en/TNDM-Investor-News-If-You-Have-Suffered-Losses-in-Tandem-Diabetes-Care-Inc-NASDAQ-TNDM-You-Are-Encouraged-to-Contact-The-Rosen-Law-Firm-About-Your-Rights.html

Trending Today

XRP ($XRP) Crypto Forecast: Down 12.8% Today

Ethereum ($ETH) Crypto Forecast: Down 10.3% Today

Silver ($XAG) Commodity Forecast: Down 6.2% Today

Jupiter ($JUP) Crypto Forecast: Down 17.9% Today

ZCash ($ZEC) Crypto Forecast: Down 16.5% Today

Monero ($XMR) Crypto Forecast: Down 20.5% Today

Bitcoin ($BTC) Crypto Forecast: Down 9.5% Today

Copper ($COPPER) Commodity Forecast: Down 5.2% Today

TRON ($TRX) Crypto Forecast: Down 5.1% Today

Gold ($XAU) Commodity Forecast: Down 5.1% Today

Tandem Diabetes Care, Inc. Price History

21.00.2026 - TNDM Stock was up 5.1%

• TNDM's stock price has increased by 36.3% in the last three months despite previous declines, which likely contributed to today's positive movement.
• An inquiry into potential securities claims against TNDM and concerns about misleading business information may have led to an initial stock price drop. However, today's market response suggests growing confidence in the company's future.
• Issues with certain t:slim X2 insulin pumps resulted in a significant stock decrease, causing investor unease. The subsequent recovery indicates a reevaluation of the pumps' impact on TNDM's performance.
• Analysts considering TNDM undervalued and providing fair value estimates based on projected growth and product advancements possibly influenced today's bullish activity, reflecting investor optimism about the company's future prospects.

30.00.2026 - TNDM Stock was up 6.0%

• The positive movement in TNDM is attributed to an improved growth outlook and strong Q4 results, as indicated in an investor letter by Meridian Growth Fund.
• Despite facing a legal investigation related to a voluntary correction for its insulin pumps, TNDM is seen as undervalued, sparking investor interest in the stock.
• An article raising concerns about weak sales volumes and declining ROIC might have initially impacted the stock negatively, but overall optimism about growth prospects and product advancements likely drove the bullish movement.
• Investors are focusing on TNDM's growth potential in the diabetes care market and product innovations, disregarding short-term challenges, which has driven the stock price higher.

13.00.2026 - TNDM Stock was down 5.1%

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

22.11.2025 - TNDM Stock was up 5.1%

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

09.00.2026 - TNDM Stock was down 9.7%

• Today's downward movement in TNDM stock could be tied to market expectations for the upcoming Q4 2025 earnings. Analysts foresee a decline in revenue and a wider loss compared to the previous year. Key metrics such as gross margin, pump shipments, and international sales are closely watched, prompting investors to review their positions. Concerns about the company's market position and growth strategies might have shifted market sentiment, leading to a stock sell-off.

03.01.2026 - TNDM Stock was down 7.0%

• TNDM faced a downward trend following the announcement of a voluntary medical device correction for its t:slim X2 insulin pumps.
• The correction addressed a possible speaker-related issue that could disrupt insulin delivery, sparking concerns about the product's reliability.
• A probe by the Rosen Law Firm into potential securities claims exacerbated the negative sentiment surrounding TNDM and led to a significant drop in the stock price.
• Investors reacted strongly to these developments, reflecting apprehensions about the potential impact on Tandem Diabetes Care's financial performance and reputation.

28.00.2026 - TNDM Stock was down 5.1%

• The improved growth outlook and better-than-expected results in Q4 boosted TNDM initially, but concerns over weak sales volumes, declining ROIC, and restricted access to capital led to a bearish movement.
• The device correction for its insulin pumps and the securities probe raised doubts about the company's risk controls and disclosure practices, impacting investor confidence.
• The investigation into potentially misleading business information following the medical device correction announcement further added to the negative sentiment surrounding TNDM.
• Overall, the combination of regulatory challenges, financial concerns, and legal investigations likely contributed to the bearish movement in TNDM's stock today.

16.11.2025 - TNDM Stock was up 6.4%

• The company was upgraded to "Outperform" from "Neutral" by Baird, accompanied by an increased price target. This adjustment signals a favorable outlook on the company's financial future, potentially contributing to the upward movement.
• A previous investigation into a securities class action following a stock decline due to a voluntary medical device correction may have led to initial uncertainty and a decrease in the stock price. However, the subsequent positive outlook and upgrade likely played a role in driving the upward movement.
• While concerns existed regarding pump demand and negative EBITDA, the recent price surge and a possible undervaluation, as indicated by Simply Wall St's DCF model, could have attracted investors, thereby leading to the uptrend.
• In summary, a combination of optimistic analyst assessments, potential undervaluation, and anticipated future growth opportunities probably fueled today's upward movement in Tandem Diabetes Care's stock.

16.00.2026 - TNDM Stock was up 5.3%

• TNDM exceeded revenue expectations in Q3 despite facing a loss, demonstrating resilience amid market challenges.
• Analysts' consensus "Hold" rating on TNDM reflects a cautious outlook on the stock.
• Noteworthy institutional investors such as Assenagon Asset Management S.A. acquiring a considerable stake in TNDM may have fueled the bullish trend, indicating confidence in the company's future.
• AI-generated trading strategies have hinted at potential downside risks, causing some investors to consider this alongside TNDM's positive revenue performance.

20.10.2025 - TNDM Stock was up 5.0%

• Investor optimism regarding TNDM stock is likely due to the recent news of an investigation by the Rosen Law Firm into potential securities claims on behalf of shareholders.
• This development may have boosted investor confidence in the company's outlook.
• The market's reaction suggests that investors are hopeful that any concerns raised in the investigation will be resolved favorably, leading to an increase in the stock price.

05.00.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care (TNDM) saw a significant increase in its stock value due to various positive factors today:
• The company is part of a group of biotech companies leading advancements in diabetes treatments, moving beyond traditional insulin shots towards functional cures and regenerative medicine, which has captured investor interest and confidence in TNDM's future.
• The anticipated growth of the disposable insulin pumps market, where Tandem Diabetes Care plays a pivotal role, suggests a promising future for the company, with the rising adoption of tubeless patch pumps fueling market expansion.
• Recent updates made by Tandem Diabetes Care to its bylaws to strengthen governance rules illustrate a dedication to transparency and accountability, reassuring investors and potentially attracting new interest in the company.
• Significant purchases of Tandem Diabetes Care stock by key executives indicate a belief in the company's direction and future expansion, offering a positive perspective for investors and contributing to the upward movement in the stock price.

10.11.2025 - TNDM Stock was up 6.1%

• The stock of Tandem Diabetes Care (TNDM) experienced a bullish movement following an analyst's target price increase to $23, leading to a 4.5% jump in the stock price.
• Despite the recent gains and analyst optimism, the stock is still down 43.3% year-to-date and trading below its 52-week high, indicating potential room for growth.
• The company's stock rebounded after a previous drop due to a voluntary medical device correction for select t:slim X2 insulin pumps, showcasing resilience in the face of challenges.
• Analysts are re-evaluating Tandem Diabetes Care's valuation, with some intrinsic value estimates below current levels, but competitive pressures and execution challenges pose risks to future growth and margin assumptions.